A registry of acromegaly patients and one year following up in Taiwan

Abstract

The objectives of this study were to describe epidemiological data, treatment outcomes, and quality of life (QOL) of patients with acromegaly in Taiwan. From 2013 to 2015, subjects with acromegaly were recruited through five medical centers. After enrollment, each patient was kept on observation for 1 year. The analyzed cohort included 272 acromegalic subjects (117 males, 155 females) with a mean age of 51.4±12.9 years. Their mean age at diagnosis was 41.8±12.1 years. About 83.8% patients presented symptoms of facial changes. Galactorrhea was noted at the earliest age of 32.7±9.1 years. The duration between the onset of symptoms/signs and diagnosis was 6.9±8.1 years. Around 70.3% patients harbored a macroadenoma. At enrollment, percentages of patients ever received surgical intervention, radiotherapy, somatostatin analogs, and dopamine agonists were 94.8%, 27.9%, 64%, and 30%, respectively. At the final following-up visit, the random growth hormone (GH), nadir GH after oral glucose tolerance test, and theinsulin-like growth factor 1 levels were 2.7±4.9μg/L, 2.4±6.1μg/L, and 291.5±162.4ng/mL, respectively. The remission rate assessed by random GH level (≦2μg/L) was 63.8%. The mean AcroQoL scores for the total 22 items were 64.0±19.7. About 42.8% patients never sensed or felt discomfort about their changes in appearance. This study described the profiles of acromegaly in Taiwan. It is important to enhance early diagnosis and timely commencement of treatment to prevent serious complications of acromegaly.